Dr. Ilonna Rimm (Harvard Medical School '81) is a healthcare investor who provides strategic advice on raising early-stage capital. She can fully understand the biological science of an emerging company. Then she can organize and polish the science to present it in a way that is attractive to life science investors. She recently provided services to Immuneering Corp., who raised a Series A round of $20M in January, 2020, and a Series B round of $62M in January, 2021. Ben Zeskind, PhD MBA, the CEO of Immuneering, is an HBS alum. Ilonna's advisory skills were developed during twenty years of Financial Services work on the Buy and Sell side of public equity, the Buy side of private equity and in the pharmaceutical industry. Ilonna also provides Expert Witness services, related to her knowledge of the valuation of early-stage healthcare companies.
Can help with
- Capital raising
- Pitch decks
- Valuation
- Investor insights and connections
- Scientific and clinical knowledge
